SEHK:1177Pharmaceuticals
Assessing Sino Biopharmaceutical’s Valuation After Positive TQA3605 Phase II Hepatitis B Trial Results
Why the TQA3605 trial update matters for Sino Biopharmaceutical
Sino Biopharmaceutical (SEHK:1177) has drawn investor attention after reporting that its HBV candidate TQA3605 met the primary endpoint in a Phase II trial, combining with nucleos(t)ide analogues for chronic hepatitis B patients.
The randomized, double blind, placebo controlled study enrolled 122 subjects and compared several TQA3605 dose groups with a nucleos(t)ide analogue only control arm. All active dose groups reached around...